Usually, no, not yet
For anxiety with chronic disease (ACD), the removal of one article (Mojtahedi et al., 2024) resulted in a substantial reduction in heterogeneity, with the I 2 value decreasing from 84% to 0%, while the treatment effect remained statistically significant, changing from SMD -0.32 (95% CI: 0.50, 0.15) to SMD -0.22 (95% CI: 0.40, 0.05)
Environmental factors, such as increased exposure to lead, cadmium, and arsenic
In this study, mean bodyweight was reduced between baseline and week 68 in the semaglutide 2.4 mg (13.2%) and semaglutide 1.7 mg (9.6%) groups when compared with the placebo group
Some people exploring GLP-1 medications talk about microdosing, which means using amounts lower than the doses studied in large clinical trials
Or just provide a customer service # so I can call.